24 April 2023
19 April 2023
26 April 2023
-
13 February 2024
-
13 February 2024
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
PARIS, FRANCE, 13 February 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus oxaliplatin, fluorour...
-
13 May 2023
-
13 May 2023
-
13 May 2023
-
13 May 2023
-
05 May 2023
-
05 May 2023
-
13 May 2023
-
13 May 2023
-
13 May 2023
-
13 May 2023
-
14 May 2023
-
14 May 2023